Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Executes Stock Option and Sells Shares
SEC Form 4 Filing
CEO Samarth Kulkarni exercised stock options and sold CRISPR Therapeutics shares on March 15, 2024, according to a recent SEC filing.
Summary
- On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics AG, exercised stock options to acquire 20,000 common shares at a price of $19.12 per share.
- Kulkarni then sold 10,613 shares at a weighted average price of $71.9693 and 9,387 shares at a weighted average price of $73.0604.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2023.
- Following these transactions, Kulkarni directly owns 208,122 common shares and indirectly owns 200,000 shares through The Kulkarni 2023 GRAT.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports transactions. The use of a 10b5-1 plan suggests pre-planned activity, reducing potential negative interpretations.
Industry Context
Insider transactions are routinely monitored and reported, providing transparency into management's perspective on the company's value. The use of a pre-arranged 10b5-1 trading plan suggests a planned and orderly approach to these transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2017-12-01 | Stock option granted with respect to 260,000 Common Shares |
| 2018-01-01 | Vesting of stock options began in 48 equal monthly installments |
| 2023-09-15 | Rule 10b5-1 trading plan adopted by the reporting person |
| 2024-03-15 | Exercise of stock options and sale of common shares |
| 2024-03-18 | Date of signature on the SEC Form 4 |
| 2027-12-01 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.